Rapid Dose Therapeutics Corp. DOSE
CNSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.87M | 2.00M | 1.99M | 1.88M | 1.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.87M | 2.00M | 1.99M | 1.88M | 1.77M |
| Cost of Revenue | 936.60K | 1.02M | 983.10K | 902.50K | 823.60K |
| Gross Profit | 930.80K | 982.40K | 1.00M | 976.60K | 941.70K |
| SG&A Expenses | 1.91M | 2.15M | 2.81M | 3.07M | 3.32M |
| Depreciation & Amortization | 362.70K | 370.30K | 326.20K | 270.50K | 208.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.24M | 3.56M | 4.17M | 4.31M | 4.43M |
| Operating Income | -1.37M | -1.56M | -2.19M | -2.43M | -2.66M |
| Income Before Tax | -2.29M | -2.44M | -3.11M | -3.28M | -3.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.29 | -2.44 | -3.11 | -3.28 | -3.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.29M | -2.44M | -3.11M | -3.28M | -3.48M |
| EBIT | -1.37M | -1.56M | -2.19M | -2.43M | -2.66M |
| EBITDA | -1.26M | -1.39M | -2.01M | -2.25M | -2.47M |
| EPS Basic | -0.02 | -0.02 | -0.03 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.02 | -0.02 | -0.03 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 487.34M | 482.38M | 471.36M | 463.86M | 504.43M |
| Average Diluted Shares Outstanding | 487.34M | 482.38M | 471.36M | 463.86M | 504.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |